CVM Key Stats
- CEL SCI CORP Financials May 17
- CEL-SCI Corporation Reports Second Quarter 2013 Financial Results Business Wire May 10
- CEL SCI CORP Files SEC form 10-Q, Quarterly Report May 10
- CEL-SCI presents data on LEAPS vaccine May 6
- CEL-SCI Presents Data Showing LEAPS Vaccine is Successful in Reducing Rheumatoid... May 6
- NEW STORY CEL-SCI to Present at the American Association of Immunologists 100th ... May 3
- CEL-SCI To Present at the American Association of Immunologists 100th Annual Mee... May 3
- Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! Apr 26
- Bullish $10 Million Bet Placed by CRO After CEL-SCI Acts to Accelerate Phase III... Apr 24
- CEL-SCI Issues Update on Phase 3 Trial, Says Enough Patients Enrolled to Date Benzinga Apr 23
CVM Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). CEL-SCI Corporation is down 33.44% over the last year vs S&P 500 Total Return up 31.95%, ImmunoCellular Therapeutics down 6.27%, and Sarepta Therapeutics up 897.8%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for CVM
Pro Report PDF for CVM
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CVM Pro Report PDF
Pro Strategies Featuring CVM
Did CEL-SCI Corporation make it into our Pro Portfolio Strategies?